APO Research
Talk to an analyst

APO RESEARCH · REPORT

Combination Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Combination Vaccine Market Outlook and Growth Opportunities 2026

22 December 2025198 pages

Choose your research edition.

Industry ResearchCombination Vaccine Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Combination Vaccine Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Combination Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Combination Vaccine Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Combination Vaccine Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Combination Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Combination Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Combination Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Combination Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Combination Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Combination Vaccine market include GSK, Merck, Pfizer, Serum Institute of India, Sanofi Pasteur MSD, Sanofi Pasteur, CNBG and Biokangtai, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Combination Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Combination Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Combination Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Combination Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Combination Vaccine Segment by Company

GSK

Merck

Pfizer

Serum Institute of India

Sanofi Pasteur MSD

Sanofi Pasteur

CNBG

Biokangtai

Combination Vaccine Segment by Type

5 Combination

4 Combination

3 Combination

Other

Combination Vaccine Segment by Application

Adults

Children

Combination Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Combination Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Combination Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Combination Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Combination Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Combination Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Combination Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Combination Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Combination Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Combination Vaccine industry.

Chapter 3: Detailed analysis of Combination Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Combination Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Combination Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Combination Vaccine Industry Trends Table 2. Combination Vaccine Industry Drivers Table 3. Combination Vaccine Industry Opportunities and Challenges Table 4. Combination Vaccine Industry Restraints Table 5. Global Combination Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Combination Vaccine Revenue Share by Company (2021-2026) Table 7. Global Combination Vaccine Sales Volume by Company (k units) & (2021-2026) Table 8. Global Combination Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Combination Vaccine Average Price (US$/unit) of Company (2021-2026) Table 10. Global Combination Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Combination Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Combination Vaccine Company, Product Type & Application Table 13. Global Combination Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Combination Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 5 Combination Table 18. Significant Companies of 4 Combination Table 19. Significant Companies of 3 Combination Table 20. Significant Companies of Other Table 21. Global Combination Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Combination Vaccine Sales Volume by Type (2021-2026) & (k units) Table 23. Global Combination Vaccine Sales Volume by Type (2027-2032) & (k units) Table 24. Global Combination Vaccine Sales Volume Share by Type (2021-2026) Table 25. Global Combination Vaccine Sales Volume Share by Type (2027-2032) Table 26. Global Combination Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Combination Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Combination Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Combination Vaccine Sales Value Share by Type (2021-2026) Table 30. Global Combination Vaccine Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Adults Table 32. Significant Companies of Children Table 33. Global Combination Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Combination Vaccine Sales Volume by Application (2021-2026) & (k units) Table 35. Global Combination Vaccine Sales Volume by Application (2027-2032) & (k units) Table 36. Global Combination Vaccine Sales Volume Share by Application (2021-2026) Table 37. Global Combination Vaccine Sales Volume Share by Application (2027-2032) Table 38. Global Combination Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Combination Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Combination Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Combination Vaccine Sales Value Share by Application (2021-2026) Table 42. Global Combination Vaccine Sales Value Share by Application (2027-2032) Table 43. Global Combination Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Combination Vaccine Sales by Region (2021-2026) & (k units) Table 45. Global Combination Vaccine Sales Market Share by Region (2021-2026) Table 46. Global Combination Vaccine Sales by Region (2027-2032) & (k units) Table 47. Global Combination Vaccine Sales Market Share by Region (2027-2032) Table 48. Global Combination Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Combination Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Combination Vaccine Sales Value Share by Region (2021-2026) Table 51. Global Combination Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Combination Vaccine Sales Value Share by Region (2027-2032) Table 53. Global Combination Vaccine Market Average Price (US$/unit) by Region (2021-2026) Table 54. Global Combination Vaccine Market Average Price (US$/unit) by Region (2027-2032) Table 55. Global Combination Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global Combination Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Combination Vaccine Sales by Country (2021-2026) & (k units) Table 58. Global Combination Vaccine Sales Market Share by Country (2021-2026) Table 59. Global Combination Vaccine Sales by Country (2027-2032) & (k units) Table 60. Global Combination Vaccine Sales Market Share by Country (2027-2032) Table 61. Global Combination Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Combination Vaccine Sales Value Market Share by Country (2021-2026) Table 63. Global Combination Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Combination Vaccine Sales Value Market Share by Country (2027-2032) Table 65. GSK Company Information Table 66. GSK Business Overview Table 67. GSK Combination Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. GSK Combination Vaccine Product Portfolio Table 69. GSK Recent Development Table 70. Merck Company Information Table 71. Merck Business Overview Table 72. Merck Combination Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Merck Combination Vaccine Product Portfolio Table 74. Merck Recent Development Table 75. Pfizer Company Information Table 76. Pfizer Business Overview Table 77. Pfizer Combination Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Pfizer Combination Vaccine Product Portfolio Table 79. Pfizer Recent Development Table 80. Serum Institute of India Company Information Table 81. Serum Institute of India Business Overview Table 82. Serum Institute of India Combination Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Serum Institute of India Combination Vaccine Product Portfolio Table 84. Serum Institute of India Recent Development Table 85. Sanofi Pasteur MSD Company Information Table 86. Sanofi Pasteur MSD Business Overview Table 87. Sanofi Pasteur MSD Combination Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Sanofi Pasteur MSD Combination Vaccine Product Portfolio Table 89. Sanofi Pasteur MSD Recent Development Table 90. Sanofi Pasteur Company Information Table 91. Sanofi Pasteur Business Overview Table 92. Sanofi Pasteur Combination Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Sanofi Pasteur Combination Vaccine Product Portfolio Table 94. Sanofi Pasteur Recent Development Table 95. CNBG Company Information Table 96. CNBG Business Overview Table 97. CNBG Combination Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. CNBG Combination Vaccine Product Portfolio Table 99. CNBG Recent Development Table 100. Biokangtai Company Information Table 101. Biokangtai Business Overview Table 102. Biokangtai Combination Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Biokangtai Combination Vaccine Product Portfolio Table 104. Biokangtai Recent Development Table 105. Key Raw Materials Table 106. Raw Materials Key Suppliers Table 107. Combination Vaccine Distributors List Table 108. Combination Vaccine Customers List Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Combination Vaccine Product Image Figure 2. Global Combination Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Combination Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Combination Vaccine Sales (2021-2032) & (k units) Figure 5. Global Combination Vaccine Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Combination Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 5 Combination Image Figure 10. 4 Combination Image Figure 11. 3 Combination Image Figure 12. Other Image Figure 13. Global Combination Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Combination Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Combination Vaccine Sales Volume Share by Type (2021-2032) Figure 16. Global Combination Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Combination Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Combination Vaccine Sales Value Share by Type (2021-2032) Figure 19. Adults Image Figure 20. Children Image Figure 21. Global Combination Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Combination Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Combination Vaccine Sales Volume Share by Application (2021-2032) Figure 24. Global Combination Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Combination Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Combination Vaccine Sales Value Share by Application (2021-2032) Figure 27. Global Combination Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global Combination Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Combination Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Combination Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Combination Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. North America Combination Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Combination Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Combination Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Combination Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Combination Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Combination Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. South America Combination Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Combination Vaccine Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Combination Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Combination Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Combination Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Combination Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Combination Vaccine Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Combination Vaccine Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • 5 Combination
  • 4 Combination
  • 3 Combination
  • Other
Applications
  • Adults
  • Children
Companies covered
  • GSK
  • Merck
  • Pfizer
  • Serum Institute of India
  • Sanofi Pasteur MSD
  • Sanofi Pasteur
  • CNBG
  • Biokangtai

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Combination Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Combination Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Combination Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Combination Vaccine Market Dynamics
  1. 2.1 Combination Vaccine Industry Trends
  2. 2.2 Combination Vaccine Industry Drivers
  3. 2.3 Combination Vaccine Industry Opportunities and Challenges
  4. 2.4 Combination Vaccine Industry Restraints
3 Combination Vaccine Market by Company
  1. 3.1 Global Combination Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Combination Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Combination Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Combination Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Combination Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Combination Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Combination Vaccine Company Product Type and Application
  8. 3.8 Global Combination Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Combination Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Combination Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Combination Vaccine Market by Type
  1. 4.1 Combination Vaccine Type Introduction
  2. 4.1.1 5 Combination
  3. 4.1.2 4 Combination
  4. 4.1.3 3 Combination
  5. 4.1.4 Other
  6. 4.2 Global Combination Vaccine Sales Volume by Type
  7. 4.2.1 Global Combination Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Combination Vaccine Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Combination Vaccine Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Combination Vaccine Sales Value by Type
  11. 4.3.1 Global Combination Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Combination Vaccine Sales Value by Type (2021-2032)
  13. 4.3.3 Global Combination Vaccine Sales Value Share by Type (2021-2032)
5 Combination Vaccine Market by Application
  1. 5.1 Combination Vaccine Application Introduction
  2. 5.1.1 Adults
  3. 5.1.2 Children
  4. 5.2 Global Combination Vaccine Sales Volume by Application
  5. 5.2.1 Global Combination Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Combination Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Combination Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Combination Vaccine Sales Value by Application
  9. 5.3.1 Global Combination Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Combination Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Combination Vaccine Sales Value Share by Application (2021-2032)
6 Combination Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Combination Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Combination Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Combination Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Combination Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Combination Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Combination Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Combination Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Combination Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Combination Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Combination Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Combination Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Combination Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Combination Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Combination Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Combination Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Combination Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Combination Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Combination Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Combination Vaccine Sales Value Share by Country, 2025 VS 2032
7 Combination Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Combination Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Combination Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Combination Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Combination Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Combination Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Combination Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Combination Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Combination Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Combination Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Combination Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Combination Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Combination Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Combination Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Combination Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Combination Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Combination Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Combination Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Combination Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Combination Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Combination Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Combination Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Combination Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Combination Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Combination Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Combination Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Combination Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Combination Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Combination Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Combination Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Combination Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Combination Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Combination Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Combination Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Combination Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Combination Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Combination Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Combination Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Combination Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Combination Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Combination Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 GSK Combination Vaccine Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Combination Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck Combination Vaccine Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Combination Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Combination Vaccine Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Serum Institute of India
  20. 8.4.1 Serum Institute of India Company Information
  21. 8.4.2 Serum Institute of India Business Overview
  22. 8.4.3 Serum Institute of India Combination Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Serum Institute of India Combination Vaccine Product Portfolio
  24. 8.4.5 Serum Institute of India Recent Developments
  25. 8.5 Sanofi Pasteur MSD
  26. 8.5.1 Sanofi Pasteur MSD Company Information
  27. 8.5.2 Sanofi Pasteur MSD Business Overview
  28. 8.5.3 Sanofi Pasteur MSD Combination Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi Pasteur MSD Combination Vaccine Product Portfolio
  30. 8.5.5 Sanofi Pasteur MSD Recent Developments
  31. 8.6 Sanofi Pasteur
  32. 8.6.1 Sanofi Pasteur Company Information
  33. 8.6.2 Sanofi Pasteur Business Overview
  34. 8.6.3 Sanofi Pasteur Combination Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sanofi Pasteur Combination Vaccine Product Portfolio
  36. 8.6.5 Sanofi Pasteur Recent Developments
  37. 8.7 CNBG
  38. 8.7.1 CNBG Company Information
  39. 8.7.2 CNBG Business Overview
  40. 8.7.3 CNBG Combination Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 CNBG Combination Vaccine Product Portfolio
  42. 8.7.5 CNBG Recent Developments
  43. 8.8 Biokangtai
  44. 8.8.1 Biokangtai Company Information
  45. 8.8.2 Biokangtai Business Overview
  46. 8.8.3 Biokangtai Combination Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Biokangtai Combination Vaccine Product Portfolio
  48. 8.8.5 Biokangtai Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Combination Vaccine Value Chain Analysis
  2. 9.1.1 Combination Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Combination Vaccine Sales Mode & Process
  6. 9.2 Combination Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Combination Vaccine Distributors
  9. 9.2.3 Combination Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst